IL264825B - Mesenchymal cell-derived exosomes to treat neurological disorders - Google Patents
Mesenchymal cell-derived exosomes to treat neurological disordersInfo
- Publication number
- IL264825B IL264825B IL264825A IL26482519A IL264825B IL 264825 B IL264825 B IL 264825B IL 264825 A IL264825 A IL 264825A IL 26482519 A IL26482519 A IL 26482519A IL 264825 B IL264825 B IL 264825B
- Authority
- IL
- Israel
- Prior art keywords
- msc
- exosomes
- btbr
- mesenchymal stem
- saline
- Prior art date
Links
- 210000001808 exosome Anatomy 0.000 title claims description 68
- 238000011282 treatment Methods 0.000 title claims description 37
- 210000004027 cell Anatomy 0.000 title description 38
- 208000012902 Nervous system disease Diseases 0.000 title description 24
- 208000025966 Neurological disease Diseases 0.000 title description 23
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims description 89
- 239000008194 pharmaceutical composition Substances 0.000 claims description 18
- 208000029560 autism spectrum disease Diseases 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 9
- 208000029726 Neurodevelopmental disease Diseases 0.000 claims description 8
- 201000000980 schizophrenia Diseases 0.000 claims description 7
- 210000001185 bone marrow Anatomy 0.000 claims description 6
- 230000000735 allogeneic effect Effects 0.000 claims description 4
- 101000958041 Homo sapiens Musculin Proteins 0.000 claims description 3
- 210000003074 dental pulp Anatomy 0.000 claims description 3
- 102000046949 human MSC Human genes 0.000 claims description 3
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 2
- 210000000577 adipose tissue Anatomy 0.000 claims description 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 2
- 208000006011 Stroke Diseases 0.000 claims 1
- 239000002245 particle Substances 0.000 description 89
- 239000011780 sodium chloride Substances 0.000 description 66
- 241000699670 Mus sp. Species 0.000 description 65
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 62
- 238000000034 method Methods 0.000 description 36
- 230000003997 social interaction Effects 0.000 description 27
- 230000000694 effects Effects 0.000 description 25
- 230000006399 behavior Effects 0.000 description 24
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 20
- 108090000623 proteins and genes Proteins 0.000 description 17
- 238000012360 testing method Methods 0.000 description 17
- 230000003989 repetitive behavior Effects 0.000 description 16
- 208000013406 repetitive behavior Diseases 0.000 description 16
- 241000699666 Mus <mouse, genus> Species 0.000 description 15
- 102000004169 proteins and genes Human genes 0.000 description 15
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 14
- 229940025084 amphetamine Drugs 0.000 description 14
- 239000002609 medium Substances 0.000 description 14
- 239000003636 conditioned culture medium Substances 0.000 description 12
- 238000002347 injection Methods 0.000 description 12
- 239000007924 injection Substances 0.000 description 12
- 208000024891 symptom Diseases 0.000 description 12
- 210000004379 membrane Anatomy 0.000 description 11
- 239000012528 membrane Substances 0.000 description 11
- 230000001965 increasing effect Effects 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 206010003805 Autism Diseases 0.000 description 9
- 208000020706 Autistic disease Diseases 0.000 description 9
- 210000004556 brain Anatomy 0.000 description 9
- 238000002296 dynamic light scattering Methods 0.000 description 9
- 238000003556 assay Methods 0.000 description 8
- 230000004071 biological effect Effects 0.000 description 8
- 230000001149 cognitive effect Effects 0.000 description 8
- 208000024827 Alzheimer disease Diseases 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 238000004891 communication Methods 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 230000009885 systemic effect Effects 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 230000006735 deficit Effects 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 230000003370 grooming effect Effects 0.000 description 5
- 238000007427 paired t-test Methods 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 239000012981 Hank's balanced salt solution Substances 0.000 description 4
- 208000018737 Parkinson disease Diseases 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 230000008014 freezing Effects 0.000 description 4
- 238000007710 freezing Methods 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 210000001178 neural stem cell Anatomy 0.000 description 4
- 108091033319 polynucleotide Proteins 0.000 description 4
- 102000040430 polynucleotide Human genes 0.000 description 4
- 239000002157 polynucleotide Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000002054 transplantation Methods 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 3
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000001464 adherent effect Effects 0.000 description 3
- 230000003750 conditioning effect Effects 0.000 description 3
- 230000007717 exclusion Effects 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 238000005194 fractionation Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 210000004392 genitalia Anatomy 0.000 description 3
- 230000002296 hyperlocomotor Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000010365 information processing Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 230000029082 maternal behavior Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 108091070501 miRNA Proteins 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 230000008092 positive effect Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 229960004308 acetylcysteine Drugs 0.000 description 2
- 210000001789 adipocyte Anatomy 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000009227 behaviour therapy Methods 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000034303 cell budding Effects 0.000 description 2
- 230000008568 cell cell communication Effects 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000001143 conditioned effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 230000003137 locomotive effect Effects 0.000 description 2
- 230000006742 locomotor activity Effects 0.000 description 2
- 230000008774 maternal effect Effects 0.000 description 2
- 239000002679 microRNA Substances 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- 210000002487 multivesicular body Anatomy 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 108010000685 platelet-derived growth factor AB Proteins 0.000 description 2
- 230000011514 reflex Effects 0.000 description 2
- 210000001995 reticulocyte Anatomy 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 230000011273 social behavior Effects 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 102100022464 5'-nucleotidase Human genes 0.000 description 1
- 241001270131 Agaricus moelleri Species 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 206010002942 Apathy Diseases 0.000 description 1
- 241000908115 Bolivar Species 0.000 description 1
- 102100024210 CD166 antigen Human genes 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010012239 Delusion Diseases 0.000 description 1
- 102100037241 Endoglin Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 description 1
- 101000980840 Homo sapiens CD166 antigen Proteins 0.000 description 1
- 101000881679 Homo sapiens Endoglin Proteins 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 description 1
- 101000610551 Homo sapiens Prominin-1 Proteins 0.000 description 1
- 101001092197 Homo sapiens RNA binding protein fox-1 homolog 3 Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102100023915 Insulin Human genes 0.000 description 1
- 102100025304 Integrin beta-1 Human genes 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 229920005372 Plexiglas® Polymers 0.000 description 1
- 102100040120 Prominin-1 Human genes 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 206010061921 Psychotic disorder due to a general medical condition Diseases 0.000 description 1
- 102100035530 RNA binding protein fox-1 homolog 3 Human genes 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 108010074686 Selenoproteins Proteins 0.000 description 1
- 102000008114 Selenoproteins Human genes 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 206010041243 Social avoidant behaviour Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 description 1
- 208000000323 Tourette Syndrome Diseases 0.000 description 1
- 208000016620 Tourette disease Diseases 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000000561 anti-psychotic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000003293 cardioprotective effect Effects 0.000 description 1
- 210000003321 cartilage cell Anatomy 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000002583 cell-derived microparticle Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000007278 cognition impairment Effects 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 231100000868 delusion Toxicity 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 201000006517 essential tremor Diseases 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 108060000864 flotillin Proteins 0.000 description 1
- 102000010660 flotillin Human genes 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 150000002270 gangliosides Chemical class 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000003825 glutamate receptor antagonist Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 210000004884 grey matter Anatomy 0.000 description 1
- 230000021061 grooming behavior Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000009808 hippocampal neurogenesis Effects 0.000 description 1
- 230000002631 hypothermal effect Effects 0.000 description 1
- 210000001822 immobilized cell Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000012482 interaction analysis Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 235000021109 kimchi Nutrition 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000003140 lateral ventricle Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 240000004308 marijuana Species 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000002241 neurite Anatomy 0.000 description 1
- 230000003188 neurobehavioral effect Effects 0.000 description 1
- 230000001123 neurodevelopmental effect Effects 0.000 description 1
- 230000004766 neurogenesis Effects 0.000 description 1
- 239000000712 neurohormone Substances 0.000 description 1
- 230000001703 neuroimmune Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 238000012346 open field test Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000009984 peri-natal effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 229950010883 phencyclidine Drugs 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 239000003016 pheromone Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000012514 protein characterization Methods 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 238000011808 rodent model Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000011870 unpaired t-test Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662374852P | 2016-08-14 | 2016-08-14 | |
| PCT/IL2017/050899 WO2018033911A1 (en) | 2016-08-14 | 2017-08-14 | Mesenchymal cell-derived exosomes to treat neurological disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL264825A IL264825A (cg-RX-API-DMAC7.html) | 2019-04-30 |
| IL264825B true IL264825B (en) | 2022-08-01 |
Family
ID=61196484
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL264825A IL264825B (en) | 2016-08-14 | 2017-08-14 | Mesenchymal cell-derived exosomes to treat neurological disorders |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11129852B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3496730B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7014449B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN109843305B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2017311684B2 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2925527T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL264825B (cg-RX-API-DMAC7.html) |
| PL (1) | PL3496730T3 (cg-RX-API-DMAC7.html) |
| SG (1) | SG11201901272WA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018033911A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11648260B2 (en) | 2018-03-29 | 2023-05-16 | Technion Research And Development Foundation Limitted | Vesicles comprising a PTEN inhibitor and uses of same |
| CA3112505C (en) * | 2018-09-20 | 2023-06-20 | Citospin, S.L. | Method for obtaining an enriched population of functional mesenchymal stem cells, cells obtained thereof and compositions comprising the same |
| EP3990625A4 (en) | 2019-06-26 | 2023-07-19 | Technion Research & Development Foundation Limited | PRODUCTION OF EXTRACELLULAR VESICLES FROM STEM CELLS |
| JP6830286B1 (ja) | 2020-06-26 | 2021-02-17 | デクソンファーマシューティカルズ株式会社 | 精巣機能改善剤および精巣機能改善方法 |
| US20230210910A1 (en) | 2020-07-17 | 2023-07-06 | Dexon Pharmaceuticals Inc. | Method for preventing infection of a healthy person or a healthy animal with a virus that uses ace2 as a receptor, binding inhibitor and medical device |
| EP4212163A4 (en) | 2020-09-08 | 2024-09-18 | Dexon Pharmaceuticals Inc. | CYTOKINE STORM INHIBITOR, METHOD FOR USING CYTOKINE STORM INHIBITOR, AND METHOD FOR SCREENING CYTOKINE INHIBITOR |
| JP6974892B1 (ja) | 2021-05-27 | 2021-12-01 | デクソンファーマシューティカルズ株式会社 | 癌悪液質の改善剤および癌悪液質の改善方法 |
| JP7492757B2 (ja) | 2022-03-22 | 2024-05-30 | Ｄｅｘｏｎファーマシューティカルズ株式会社 | 遺伝子の発現制御剤、アルツハイマー病の予防薬または治療薬および認知症の改善方法 |
| US20250136992A1 (en) | 2022-05-15 | 2025-05-01 | Nurexone Biologic Ltd. | Anti-pten rna interference oligonucleotides and uses thereof |
| CN115006427A (zh) * | 2022-05-31 | 2022-09-06 | 尧舜泽生物医药(南京)有限公司 | 骨髓间充质干细胞外泌体在治疗帕金森病中的应用 |
| EP4541359A1 (en) | 2022-06-20 | 2025-04-23 | Dexon Pharmaceuticals Inc. | Ptx3 expression control agent, prophylactic drug or therapeutic drug for vasculitis or hardening of skin associated with rheumatoid arthritis, autoimmune disease, method for improving vasculitis or hardening of skin associated with rheumatoid arthritis, autoimmune disease |
| WO2023248844A1 (ja) | 2022-06-20 | 2023-12-28 | Ｄｅｘｏｎファーマシューティカルズ株式会社 | Ｈｍｇｂ１の発現制御剤；急性肺損傷、急性呼吸窮迫症候群または敗血症の予防薬または治療薬、あるいはそれらの改善方法 |
| CN120078807B (zh) * | 2025-02-08 | 2026-03-31 | 广东省人民医院 | 改善卵巢功能的MSC-sEVs药物及其制备方法和应用 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154600B (nl) | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| NL154599B (nl) | 1970-12-28 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking. |
| US3901654A (en) | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
| US3853987A (en) | 1971-09-01 | 1974-12-10 | W Dreyer | Immunological reagent and radioimmuno assay |
| US3867517A (en) | 1971-12-21 | 1975-02-18 | Abbott Lab | Direct radioimmunoassay for antigens and their antibodies |
| NL171930C (nl) | 1972-05-11 | 1983-06-01 | Akzo Nv | Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen. |
| US3850578A (en) | 1973-03-12 | 1974-11-26 | H Mcconnell | Process for assaying for biologically active molecules |
| US3935074A (en) | 1973-12-17 | 1976-01-27 | Syva Company | Antibody steric hindrance immunoassay with two antibodies |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4034074A (en) | 1974-09-19 | 1977-07-05 | The Board Of Trustees Of Leland Stanford Junior University | Universal reagent 2-site immunoradiometric assay using labelled anti (IgG) |
| US3984533A (en) | 1975-11-13 | 1976-10-05 | General Electric Company | Electrophoretic method of detecting antigen-antibody reaction |
| US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
| US4879219A (en) | 1980-09-19 | 1989-11-07 | General Hospital Corporation | Immunoassay utilizing monoclonal high affinity IgM antibodies |
| US5011771A (en) | 1984-04-12 | 1991-04-30 | The General Hospital Corporation | Multiepitopic immunometric assay |
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| US5486359A (en) | 1990-11-16 | 1996-01-23 | Osiris Therapeutics, Inc. | Human mesenchymal stem cells |
| US5281521A (en) | 1992-07-20 | 1994-01-25 | The Trustees Of The University Of Pennsylvania | Modified avidin-biotin technique |
| US20060188496A1 (en) * | 2005-02-23 | 2006-08-24 | Hanne Bentz | Intranasal administration of active agents to the central nervous system |
| WO2008036374A2 (en) * | 2006-09-21 | 2008-03-27 | Medistem Laboratories, Inc. | Allogeneic stem cell transplants in non-conditioned recipients |
| AU2009203638C1 (en) | 2008-01-04 | 2013-07-25 | Lydac Neuroscience Limited | Microvesicles |
| EP2254586B1 (en) | 2008-02-22 | 2015-04-08 | Agency For Science, Technology And Research (A*star) | Mesenchymal stem cell particles |
| KR20100054711A (ko) * | 2008-11-14 | 2010-05-25 | 메디포스트(주) | 간엽 줄기세포 또는 이의 배양액을 포함하는 신경질환의 예방 또는 치료용 조성물 |
| CN102596177B (zh) * | 2009-07-01 | 2014-05-28 | 阿昂梅迪克斯公司 | 来源于有核哺乳动物细胞的微囊泡及其应用 |
| JPWO2011118795A1 (ja) | 2010-03-26 | 2013-07-04 | 国立大学法人名古屋大学 | 損傷部治療用組成物 |
| JP5608927B2 (ja) * | 2010-04-13 | 2014-10-22 | 国立大学法人名古屋大学 | 歯髄幹細胞を用いた神経疾患治療用組成物 |
| GB201011589D0 (en) | 2010-07-09 | 2010-08-25 | Reneuron Ltd | Therapeutic cells |
| WO2012020308A2 (en) * | 2010-08-13 | 2012-02-16 | The University Court Of The University Of Glasgow | Cellular and molecular therapies |
| WO2012068170A2 (en) * | 2010-11-15 | 2012-05-24 | Jau-Nan Lee | Generation of neural stem cells from human trophoblast stem cells |
| WO2012156968A2 (en) * | 2011-05-19 | 2012-11-22 | Ariel - University Research And Development Company, Ltd. | Use of mesenchymal stem cells for the improvement of affective and cognitive function |
| WO2013124817A2 (en) * | 2012-02-22 | 2013-08-29 | Brainstem Biotec Ltd. | MicroRNAS FOR THE GENERATION OF ASTROCYTES |
| EP2833893B1 (en) | 2012-04-03 | 2018-08-29 | Reneuron Limited | Stem cell microparticles |
| WO2013186735A2 (en) | 2012-06-14 | 2013-12-19 | Bar-Ilan Research And Development Company Ltd. | Photothermal detection |
| WO2015038075A1 (en) * | 2013-09-16 | 2015-03-19 | Agency For Science, Technology And Research | Method |
| WO2016149358A1 (en) | 2015-03-16 | 2016-09-22 | Duncan Ross | Method of treatment comprising membrane-enclosed vesicle |
-
2017
- 2017-08-14 IL IL264825A patent/IL264825B/en unknown
- 2017-08-14 US US16/325,445 patent/US11129852B2/en active Active
- 2017-08-14 PL PL17841210.2T patent/PL3496730T3/pl unknown
- 2017-08-14 WO PCT/IL2017/050899 patent/WO2018033911A1/en not_active Ceased
- 2017-08-14 SG SG11201901272WA patent/SG11201901272WA/en unknown
- 2017-08-14 EP EP17841210.2A patent/EP3496730B1/en active Active
- 2017-08-14 AU AU2017311684A patent/AU2017311684B2/en active Active
- 2017-08-14 ES ES17841210T patent/ES2925527T3/es active Active
- 2017-08-14 JP JP2019508178A patent/JP7014449B2/ja active Active
- 2017-08-14 CN CN201780063347.2A patent/CN109843305B/zh active Active
-
2021
- 2021-08-04 US US17/394,008 patent/US20210361717A1/en active Pending
Non-Patent Citations (3)
| Title |
|---|
| SEGAL-GAVISH, H ET AL., MESENCHYMAL STEM CELL TRANSPLANTATION PROMOTES NEUROGENESIS AND AMELIORATES AUTISM RELATED BEHAVIORS IN BTBR MICE., 10 August 2015 (2015-08-10) * |
| XIN, H. ET AL., SYSTEMIC ADMINISTRATION OF EXOSOMES RELEASED FROM MESENCHYMAL STROMAL CELLS PROMOTE FUNCTIONAL RECOVERY AND NEUROVASCULAR PLASTICITY AFTER STROKE IN RATS., 21 August 2013 (2013-08-21) * |
| ZHUANG, X. ET AL., TREATMENT OF BRAIN INFLAMMATORY DISEASES BY DELIVERING EXOSOME ENCAPSULATED ANTI-INFLAMMATORY DRUGS FROM THE NASAL REGION TO THE BRAIN., 13 September 2011 (2011-09-13) * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3496730A1 (en) | 2019-06-19 |
| EP3496730B1 (en) | 2022-05-25 |
| AU2017311684A2 (en) | 2019-03-28 |
| AU2017311684B2 (en) | 2023-05-04 |
| SG11201901272WA (en) | 2019-03-28 |
| JP7014449B2 (ja) | 2022-02-01 |
| AU2017311684A1 (en) | 2019-03-07 |
| JP2019524824A (ja) | 2019-09-05 |
| IL264825A (cg-RX-API-DMAC7.html) | 2019-04-30 |
| EP3496730A4 (en) | 2020-05-06 |
| CN109843305B (zh) | 2023-03-10 |
| US20210361717A1 (en) | 2021-11-25 |
| ES2925527T3 (es) | 2022-10-18 |
| CN109843305A (zh) | 2019-06-04 |
| US20190209621A1 (en) | 2019-07-11 |
| WO2018033911A1 (en) | 2018-02-22 |
| US11129852B2 (en) | 2021-09-28 |
| PL3496730T3 (pl) | 2022-09-26 |
| CA3033951A1 (en) | 2018-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20210361717A1 (en) | Mesenchymal cell-derived exosomes to treat neurological disorders | |
| Tajiri et al. | Intravenous transplants of human adipose-derived stem cell protect the brain from traumatic brain injury-induced neurodegeneration and motor and cognitive impairments: cell graft biodistribution and soluble factors in young and aged rats | |
| Peng et al. | Microglia‐derived exosomes improve spinal cord functional recovery after injury via inhibiting oxidative stress and promoting the survival and function of endothelia cells | |
| Karimi-Abdolrezaee et al. | Delayed transplantation of adult neural precursor cells promotes remyelination and functional neurological recovery after spinal cord injury | |
| US20200308547A1 (en) | Stem cell conditioned media and methods of producing the same | |
| Larsen et al. | DJ-1 knock-down impairs astrocyte mitochondrial function | |
| US10870830B2 (en) | Method for culturing differentiation-promoting and -sustaining spheroid form of tonsil-derived stem cells | |
| Barreiro et al. | Pivotal role for skin transendothelial radio-resistant anti-inflammatory macrophages in tissue repair | |
| CA2960164A1 (en) | Methods of producing and using exersomes and bioengineered exersomes | |
| JP2017526723A (ja) | 移植片対宿主病（ｇｖｈｄ）または表皮水疱症（ｅｂ）のエキソソームによる治療方法 | |
| KR20160035087A (ko) | 줄기 세포 마이크로입자 및 miRNA | |
| KR102213890B1 (ko) | 엑소좀 기반의 면역세포의 교차분화 방법 | |
| Ge et al. | Engineering EVs‐mediated mRNA delivery regulates microglia function and alleviates depressive‐like behaviors | |
| US20080075698A1 (en) | Brain-Localizing Bone Marrow Progenitor cells | |
| EP4180517A1 (en) | Pre-conditioned mesenchymal stem cells and preparations and applications thereof | |
| Shichinohe et al. | Bone marrow stromal cells and bone marrow‐derived mononuclear cells: Which are suitable as cell source of transplantation for mice infarct brain? | |
| ITUB20159750A1 (it) | Metodo per la promozione ed il miglioramento delle proprieta? del tessuto adiposo, tessuto e cellule ottenute tramite detto metodo | |
| CA3033951C (en) | Mesenchymal cell-derived exosomes to treat neurological disorders | |
| Yamazoe et al. | Efficient generation of dopaminergic neurons from mouse embryonic stem cells enclosed in hollow fibers | |
| KR20150091519A (ko) | 다계열 분화능 세포 생성 방법 | |
| JP2024529034A (ja) | 尿由来幹細胞の培養のための培地組成物、これを用いた尿由来幹細胞の分離及び培養方法、腎臓疾患治療機能が向上した尿由来幹細胞及びこれを含む細胞治療剤組成物 | |
| US20250295699A1 (en) | Methods and compositions for treating cortical hyperexcitability and reversing stroke-induced changes in gene expression and protein expression | |
| CN115554316B (zh) | SKP-SC-EVs在制备治疗帕金森病的产品中的应用 | |
| KR20250020300A (ko) | 편도 유래 중간엽 줄기세포로부터 추출된 엑소좀을 함유하는 망막변성질환 예방 또는 치료용 조성물 | |
| RU2790031C2 (ru) | Способ лечения аллергического заболевания дыхательных путей (AAD)/астмы |